New obesity drug IBI362 tested in chinese adults – could it be a game changer?
NCT ID NCT07000955
First seen Dec 16, 2025 · Last updated Apr 30, 2026 · Updated 17 times
Summary
This study tests a new drug called IBI362 in Chinese adults with moderate to severe obesity (BMI 32.5 or higher). The goal is to check the drug's safety, side effects, and how the body processes it. About 98 participants will receive either IBI362, a placebo, or an active comparator, and researchers will monitor weight changes and health markers over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Affiliated Hospital of Nanjing University Medical School
Nanjing, Jiangsu, 210003, China
Conditions
Explore the condition pages connected to this study.